Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high. Inadequate rituximab exposure due to rapid antibo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Mo, Clifton C., Njuguna, Ndegwa, Beum, Paul V., Lindorfer, Margaret A., Vire, Berengere, Lee, Elinor, Marti, Gerald, Wilson, Wyndham H, Taylor, Ronald P., Wiestner, Adrian
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2013
Assuntos:
Original Articles and Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729907/
https://ncbi.nlm.nih.gov/pubmed/23716541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.080929
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares